Baricitinib Augments Lonafarnib Therapy to Preserve Colonic Homeostasis and Microbial Balance in a Mouse Model of Progeria
Aging Cell · 2025
DOI: 10.1111/acel.70273 ↗Kurz gefasst
Fachartikel in der Zeitschrift Aging Cell, 2025. Verfasst von Moritz Schroll und 4 weiteren Autor:innen. Beteiligte Einrichtung: Epigenetics of Aging, Department of Dermatology and Allergy, TUM School of Medicine and Health, Munich Institute of Biomedical Engineering, Technical…. Hauptthemen laut MEDLINE: Progeria, Azetidines, Purines, Piperidines. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 81 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Progeria Research Foundation.
Abstract (Originalsprache)
Hutchinson‐Gilford Progeria Syndrome (HGPS) is a fatal genetic disorder caused by progerin, a mutant lamin A variant that disrupts nuclear architecture and drives systemic cellular dysfunction. Gastrointestinal (GI) involvement in HGPS remains poorly understood, despite growing evidence of gut abnormalities and microbial dysbiosis in progeroid mouse models. Here, we provide the first comprehensive characterization of colonic pathology in Lmna G609G/G609G mice and assess the therapeutic impact of baricitinib (Bar), a JAK–STAT inhibitor, lonafarnib (FTI), the only FDA‐approved therapy, and their combination on colonic health. Bar + FTI combination therapy most effectively lowered progerin levels, preserved colonic architecture and epithelial regeneration markers, while also reducing inflammation, cellular senescence, and early fibrotic changes. Notably, FTI monotherapy aggravated inflammation via STAT1 activation, an effect reversed by Bar co‐administration. Bar also emerged as the primary driver in mitigating colonic tissue senescence, highlighting its role in supporting intestinal homeostasis. In addition, we observed marked microbial dysbiosis in HGPS mice, particularly in late‐stage disease. While both monotherapies induced distinct shifts in gut microbiota, combination therapy preserved a profile more closely resembling healthy controls. These findings expand the current understanding of GI involvement in HGPS and identify the colon as a site where JAK–STAT inhibition enhances the therapeutic profile of FTI.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Epigenetics of Aging, Department of Dermatology and Allergy, TUM School of Medicine and Health, Munich Institute of Biomedical Engineering, Technical University of Munich, Garching, Germany.
- Department of Dermatology and Allergy, School of Medicine, Technical University of Munich, Munich, Germany.
- Core Facility Microbiome, ZIEL-Institute for Food & Health, Technical University of Munich, Freising, Germany.
ORCID-Profile: Moritz Schroll, Peter Krüger, Klaus Neuhaus, Karima Djabali
Förderung
- Progeria Research Foundation
Zitieren
APA
Schroll, M., Amar, Y., Krüger, P., Neuhaus, K., & Djabali, K. (2025). Baricitinib Augments Lonafarnib Therapy to Preserve Colonic Homeostasis and Microbial Balance in a Mouse Model of Progeria. Aging Cell. https://doi.org/10.1111/acel.70273
Vancouver
Schroll M, Amar Y, Krüger P, Neuhaus K, Djabali K. Baricitinib Augments Lonafarnib Therapy to Preserve Colonic Homeostasis and Microbial Balance in a Mouse Model of Progeria. Aging Cell. 2025. doi:10.1111/acel.70273
BibTeX
@article{Schroll2025,
author = {Schroll, Moritz and Amar, Yacine and Krüger, Peter and Neuhaus, Klaus and Djabali, Karima},
title = {Baricitinib Augments Lonafarnib Therapy to Preserve Colonic Homeostasis and Microbial Balance in a Mouse Model of Progeria},
journal = {Aging Cell},
year = {2025},
doi = {10.1111/acel.70273}
}
EUVIMED